1. Home
  2. SAR vs TENX Comparison

SAR vs TENX Comparison

Compare SAR & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$20.01

Market Cap

362.9M

Sector

Finance

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$13.78

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAR
TENX
Founded
2007
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.9M
317.8M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
SAR
TENX
Price
$20.01
$13.78
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$23.75
$29.67
AVG Volume (30 Days)
173.3K
1.4M
Earning Date
05-05-2026
05-15-2026
Dividend Yield
14.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.39
N/A
P/E Ratio
$9.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.34
$5.80
52 Week High
$25.64
$19.40

Technical Indicators

Market Signals
Indicator
SAR
TENX
Relative Strength Index (RSI) 46.74 42.05
Support Level $17.34 $13.13
Resistance Level $23.74 $14.15
Average True Range (ATR) 0.50 1.19
MACD 0.14 -0.36
Stochastic Oscillator 67.28 9.63

Price Performance

Historical Comparison
SAR
TENX

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: